The estimated Net Worth of Stavros G. Vizirgianakis is at least $156 Milión dollars as of 7 October 2022. Mr. Vizirgianakis owns over 2,264,861 units of Misonix Inc stock worth over $155,278,003 and over the last 12 years he sold MSON stock worth over $0. In addition, he makes $541,307 as President, Chief Executive Officer a Director at Misonix Inc.
Stavros has made over 6 trades of the Misonix Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 2,264,861 units of MSON stock worth $1,087,133 on 7 October 2022.
The largest trade he's ever made was buying 2,264,861 units of Misonix Inc stock on 7 October 2022 worth over $1,087,133. On average, Stavros trades about 149,326 units every 145 days since 2013. As of 7 October 2022 he still owns at least 5,850,716 units of Misonix Inc stock.
You can see the complete history of Mr. Vizirgianakis stock trades at the bottom of the page.
Stavros G. Vizirgianakis is an President, Chief Executive Officer, Director of the Company. Mr. Vizirgianakis became the Company’s Interim Chief Executive Officer in September 2016 and its full-time President and Chief Executive Officer in December 2016. Mr. Vizirgianakis has a distinguished career in the medical devices field having worked for United States Surgical Corporation as director of sales for sub-Saharan Africa and later Tyco Healthcare in the capacity of General Manager South Africa. In 2006, Mr. Vizirgianakis co-founded Surgical Innovations, which became one of the largest privately owned medical device distributors in the African region, and part of the Johannesburg Stock Exchange listed entity Ascendis Health. In that capacity, Mr. Vizirgianakis acted as a distributor of the Company’s products. Mr. Vizirgianakis was Managing Director of Ascendis Medical from January 2014 through July 2016. Mr. Vizirgianakis also served on the board of Tenaxis Medical and is a strategic investor and advisor to numerous medical device startups and established companies in this field. Mr. Vizirgianakis has a degree in commerce from the University of South Africa. The Board believes Mr. Vizirgianakis’ industry knowledge and his vast international business relationships qualify him to serve as a Director.
As the President, Chief Executive Officer a Director of Misonix Inc, the total compensation of Stavros Vizirgianakis at Misonix Inc is $541,307. There are no executives at Misonix Inc getting paid more.
Stavros Vizirgianakis is 47, he's been the President, Chief Executive Officer a Director of Misonix Inc since 2016. There are 2 older and no younger executives at Misonix Inc. The oldest executive at Misonix Inc is Charles Miner, 66, who is the Independent Director.
Stavros's mailing address filed with the SEC is Cruiser Lane, Belgrade, Gallatin County, Montana, 59714, United States.
Over the last 21 years, insiders at Misonix Inc have traded over $4,371,211 worth of Misonix Inc stock and bought 1,536,334 units worth $6,620,934 . The most active insiders traders include Stavros G. Vizirgianakis, Gary Gelman a Michael A Jr Mcmanus. On average, Misonix Inc executives and independent directors trade stock every 29 days with the average trade being worth of $378,885. The most recent stock trade was executed by Sharon W Klugewicz on 20 May 2020, trading 825 units of MSON stock currently worth $10,032.
Misonix, Inc. is a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative tissue products. Its surgical team markets and sells BoneScalpel and SonaStar, which facilitate precise bone sculpting and removal of soft and hard tumors and tissue, primarily in the areas of neurosurgery, orthopedic, plastic and maxillo-facial surgery. The Company's wound team markets and sells TheraSkin, Therion, TheraGenesis and SonicOne to debride, treat and heal chronic and traumatic wounds in inpatient, outpatient and physician office sites of service. At Misonix, Better Matters! That is why throughout the Company's history, Misonix has maintained its commitment to medical technology innovation and the development of products that radically improve outcomes for patients.
Misonix Inc executives and other stock owners filed with the SEC include: